Prognose

Analytikernes gennemsnitlige kursmål er 86,58 € (+36,35 %). Medianen er 86,58 € (+36,35 %).

Køb
  10
Behold
  2
Sælg
  0

Diskussioner i communityet

Der er endnu ingen diskussion om dette aktiv.

Start diskussion

  • RadNet beats Q2 forecasts and raises full-year guidance

    RadNet reported adjusted EPS of $0.29 for Q2 2026 on revenue of $622.7m, both well above consensus estimates, and posted an adjusted EBITDA quarterly record of $99.7m. Total revenue rose 25% year over year, driven by stronger demand for advanced imaging and a 56.5% increase in digital-health revenue; ARR nearly doubled to $105.5m. The company raised its full-year targets for imaging revenue, adjusted EBITDA and free cash flow. The stock rose about 6% in after-hours trading, while management highlighted accelerated adoption of AI solutions and continued wage-pressure and integration risks. » Mere på de.investing.com


  • RadNet secures $250 million loan and lowers interest costs

    RadNet has amended its existing credit agreement and taken on an additional $250 million loan, which is being combined with the existing facility (totaling $1.2087 billion) and matures on April 18, 2031. Quarterly principal payments will rise from $2.4 million to about $3.1 million. RadNet plans to use the funds for acquisitions, organic growth, healthcare partnerships and general corporate purposes. The interest rate has been cut by 0.25 percentage points (choice of Term SOFR plus 2.00% or an alternate base rate plus 1.00%), and the terms of the revolving credit line were also improved, strengthening the company’s financial flexibility with a cash position of $455 million as of March 31, 2026. » Mere på de.investing.com


  • DeepHealth (RadNet subsidiary) launches AI platform Reporting Pro for radiology reporting

    DeepHealth, a wholly owned subsidiary of RadNet, has made Reporting Pro commercially available — an AI-powered platform for creating radiology reports that combines speech recognition, clinical AI findings, measurements, generative AI assessments, and quality assurance in a single workflow. The solution incorporates both FDA-cleared and CE-marked AI tools, can integrate with existing PACS/RIS systems, and supports all imaging modalities. RadNet is rolling out Reporting Pro across its own network, has secured initial external customers, and plans to expand into additional countries by the end of the year. » Mere på de.investing.com


  • Moody's cuts rating of RadNet's senior secured bank credit facilities after $200m loan

    Moody’s downgraded RadNet’s senior secured bank credit facilities from Ba3 to B1; the Corporate Family Rating remains at B1 with a stable outlook. The downgrade follows the issuance of an additional $200 million senior loan to finance acquisitions and expansion, which raises pro forma leverage from about 4.5x to around 5.0x. Moody’s cites higher fixed costs and geographic concentration as pressure points, but highlights RadNet’s strong competitive position, revenue diversification and a pro forma liquidity position of more than $600 million, and expects leverage to decline over the next 12–18 months. » Mere på de.investing.com


  • RadNet beats revenue forecasts in Q1 2026, stock rises despite EPS miss

    RadNet reported Q1 2026 revenue of $575.63 million versus $557.64 million expected (+3.23% surprise) with EPS of $-0.28 (forecast -$0.15). Revenue rose 22.1% year over year, adjusted EBITDA increased 36.3%, and days sales outstanding (DSO) were 29.5 days. The stock climbed 8.95% in premarket trading to $63.40 as investors reacted positively to revenue growth, digital health initiatives and acquisition contributions. RadNet maintains an upbeat outlook with FY 2026 guidance of $0.63 EPS and expected revenues of $2.45 billion. » Mere på de.investing.com

Virksomhedstal

I det seneste kvartal havde RadNet en omsætning på 563,49 mio. € og et nettoresultat på 3,67 mio. €

(EUR) september 2026
YoY
Omsætning 563,49 mio. 26,47 %
Bruttofortjeneste 75,81 mio. 22,74 %
Nettoresultat 3,67 mio. 20,57 %
EBITDA 84,05 mio. 27,39 %

Fundamentale data

Nøgletal Værdi
Markedsværdi
5 mia. €
Antal aktier
78,77 mio.
Højeste/laveste i 52 uger
78,23 € - 46,31 €
Udbytte Nej
Beta
1,40
P/E (PE Ratio)
-242,22
PEG (PEG Ratio)
3,65
K/I (PB Ratio)
4,84
P/S (PS Ratio)
2,30

Virksomhedsprofil

RadNet, Inc. tilbyder sammen med sine datterselskaber ambulant diagnostisk billeddiagnostik i USA. Virksomhedens ydelser omfatter magnetisk resonanstomografi (MR), computertomografi (CT), positronemissionstomografi (PET), nuklearmedicin, mammografi, ultralyd, diagnostisk radiologi, fluoroskopi og andre relaterede procedurer samt multimodal billeddiagnostik. Selskabet udvikler og sælger også computerbaserede systemer til billeddiagnostikbranchen, herunder picture archiving and communication systems (PACS) og tilhørende serviceydelser; og udvikler og udruller AI-pakker, der forbedrer radiologers fortolkning af billeder inden for mammografi, samt AI-løsninger til lunge- og prostatakræft. Pr. 31. december 2021 ejede og drev det 347 centre i Arizona, Californien, Delaware, Florida, Maryland, New Jersey og New York. Virksomheden blev grundlagt i 1981 og har hovedkontor i Los Angeles, Californien.

Navn
RadNet
CEO
Howard G. Berger
Hjemsted Los Angeles, ca
USA
Websted
Sektor
Sundhed
Branche
Sundhedsudstyr og -produkter
Børsnotering
10.12.2021
Medarbejdere 9.060

Tickersymboler

Børs Symbol
NASDAQ
RDNT
Frankfurt
PQIA.F
Düsseldorf
PQIA.DU
SIX
PQIA.SW
🍪

Parqet  bruger cookies. Læs mere